Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years)
Hematology, Transfusion and Cell Therapy（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要